Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03480633 · ClinicalTrials.gov registry record
Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure
A clinical trial of Cardiovascular Risk Factor and Heart Failure With Reduced Ejection Fraction, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 1
- Study location
NCT03480633: Recruiting study of Cardiovascular Risk Factor and Heart Failure With Reduced Ejection Fraction, sponsored by Massachusetts General Hospital.
NCT03480633 is a study of Cardiovascular Risk Factor and Heart Failure With Reduced Ejection Fraction that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 3,000 participants, roughly in line with the 2,971-participant average among 31 other Cardiovascular Risk Factor trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03480633, a study of Cardiovascular Risk Factor and Heart Failure With Reduced Ejection Fraction, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 1
- Study location
Study Summary
In this single-center, longitudinal observational study, we will comprehensively examine clinical characteristics, proteomic, metabolomic, genomic and imaging data to better understand how different heart failure types may develop and progress over time. We will evaluate distinct sub-groups of heart failure (also known as heart failure phenotypes) and cardiomyopathies including amyloidosis with an ultimate goal of bringing the right medications and therapy to the right patients to optimize benefit and minimized side effects, an effort to improve precision medicine in heart failure.
Primary Outcome
MACE as defined by a combined end point of all-cause mortality and HF hospitalizations.
Conditions Studied
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2016-04-07 |
| Est. Completion | 2027-10-06 |
What NCT03480633 shows while recruiting
NCT03480633 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 2,971-participant average among 31 other Cardiovascular Risk Factor trials with a reported enrollment target.
The record links to 5 conditions, with Cardiovascular Risk Factor appearing as the primary indexed condition, and to 0 interventions.
NCT03480633 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03480633 about?
NCT03480633 is a clinical study titled "Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure". In this single-center, longitudinal observational study, we will comprehensively examine clinical characteristics, proteomic, metabolomic, genomic and imaging data to better understand how different heart failure types may develop and progress over time. We will evaluate distinct sub-groups of heart...
What is the current status of trial NCT03480633?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2016-04-07. Estimated completion is 2027-10-06.
What conditions does trial NCT03480633 study?
This clinical trial studies the following conditions: Cardiovascular Risk Factor, Heart Failure With Reduced Ejection Fraction, Heart Failure With Normal Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure, Right Sided.
Who is sponsoring clinical trial NCT03480633?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03480633 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Risk Factor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03480633's enrollment target sits among peer trials
3,000 4th of 31 higher than 28 of 31 other Cardiovascular Risk Factor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Risk Factor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
RECRUITING · NA
-
Community Benefit of No-charge Calcium Score Screening Program
RECRUITING
-
The Influence of Mitochondrial-Derived Reactive Oxygen Species on Racial Disparities in Neurovascular Function
RECRUITING · NA
-
Sleep Duration and Cardiovascular Health
RECRUITING · NA
-
The Potassium Supplementation Study
RECRUITING · NA
-
Mechanisms Underlying the Protective Vascular Effects of Dietary Potassium in Humans
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI